
Opinion|Videos|November 6, 2025
Managing Adverse Events and Integrating Amivantamab Plus Lazertinib
Panelists discuss how proactive AE management optimizes safety and adherence with emerging EGFR-targeted regimens.
Advertisement
Episodes in this series

Panelists discuss how effective management of adverse events (AEs) supports successful integration of novel EGFR-targeted combinations like amivantamab and lazertinib. They review toxicity profiles across therapies, noting dermatologic and infusion-related reactions as common concerns. Strategies such as early recognition, prophylactic care, and multidisciplinary support are highlighted for minimizing discontinuation rates and maintaining adherence. The discussion emphasizes that proactive AE management enhances tolerability and patient confidence, ensuring long-term therapy success.
Advertisement
Related to this article

In this Q&A, Konstantin Dmitrievich Penkov, MD, discusses delayed quality-of-life decline with cemiplimab plus chemotherapy in aNSCLC.

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

San Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.

The FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.

Earlier MASH fibrosis detection is more urgent now that treatments exist, and automating FIB-4 in EHRs could help primary care, says Rohit Loomba, MD.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.
Advertisement
Advertisement
Trending on AJMC
1
Value-Based Pilot for Medicaid Members With Substance Use Disorder
2
Health Equity & Access Weekly Roundup: November 20, 2026
3
Four Ways to Boost Awareness, Access for COVID-19 PEP
4
Acne Treatment Adherence Ranges From 6% to 84% in Real-World Studies
5

